Karen Van Nuys

899 total citations
24 papers, 590 citations indexed

About

Karen Van Nuys is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Family Practice. According to data from OpenAlex, Karen Van Nuys has authored 24 papers receiving a total of 590 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 8 papers in Pediatrics, Perinatology and Child Health and 7 papers in Family Practice. Recurrent topics in Karen Van Nuys's work include Pharmaceutical Economics and Policy (11 papers), Medication Adherence and Compliance (7 papers) and Pharmaceutical studies and practices (7 papers). Karen Van Nuys is often cited by papers focused on Pharmaceutical Economics and Policy (11 papers), Medication Adherence and Compliance (7 papers) and Pharmaceutical studies and practices (7 papers). Karen Van Nuys collaborates with scholars based in United States, Switzerland and Italy. Karen Van Nuys's co-authors include Dana P. Goldman, Darius Lakdawalla, Meghan Gallagher, Alvin C. Powers, Daniel Dawes, William T. Cefalu, William H. Herman, Marianne Laouri, Joan Fortuny and Er Chen and has published in prestigious journals such as The Lancet, JAMA and Journal of Financial Economics.

In The Last Decade

Karen Van Nuys

22 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Van Nuys United States	10	139	128	113	102	61	24	590
Dimitris Rucks Varvaki Rados Brazil	14	335 2.4×	14 0.1×	28 0.2×	43 0.4×	12 0.2×	43	673
Matthew Taylor United Kingdom	11	19 0.1×	128 1.0×	35 0.3×	38 0.4×	7 0.1×	37	373
Ward Fickweiler United States	9	27 0.2×	92 0.7×	107 0.9×	79 0.8×	4 0.1×	25	359
Tor Claudi Norway	13	351 2.5×	33 0.3×	18 0.2×	14 0.1×	15 0.2×	39	708
Nancy Reynoso‐Noverón Mexico	14	145 1.0×	50 0.4×	7 0.1×	28 0.3×	7 0.1×	67	716
Jason Tan Australia	13	20 0.1×	12 0.1×	420 3.7×	141 1.4×	49 0.8×	23	805
Rafael Venson Brazil	11	28 0.2×	39 0.3×	10 0.1×	18 0.2×	20 0.3×	21	402
Emelie Andersson Sweden	11	94 0.7×	78 0.6×	8 0.1×	16 0.2×	6 0.1×	27	442
Waqas Haque United States	10	45 0.3×	66 0.5×	7 0.1×	26 0.3×	5 0.1×	32	288
Per‐Henrik Zahl Norway	17	19 0.1×	61 0.5×	26 0.2×	57 0.6×	2 0.0×	40	1.1k

Countries citing papers authored by Karen Van Nuys

Since Specialization

Citations

This map shows the geographic impact of Karen Van Nuys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Van Nuys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Van Nuys more than expected).

Fields of papers citing papers by Karen Van Nuys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Van Nuys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Van Nuys. The network helps show where Karen Van Nuys may publish in the future.

Co-authorship network of co-authors of Karen Van Nuys

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Van Nuys. A scholar is included among the top collaborators of Karen Van Nuys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Van Nuys. Karen Van Nuys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trish, Erin, Barbara Blaylock, & Karen Van Nuys. (2025). Cost Sharing for Preferred Branded Drugs in Medicare Part D. JAMA. 333(13). 1170–1170. 3 indexed citations

Blaylock, Barbara, Karen Van Nuys, & Geoffrey Joyce. (2025). Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple Sclerosis. JAMA Network Open. 8(8). e2525155–e2525155. 1 indexed citations

Lin, Eugene, et al.. (2025). Care Continuity, Nephrologists’ Dialysis Facility Preferences, and Outcomes. JAMA Health Forum. 6(4). e250423–e250423.

Qato, Dima M., Yugen Chen, & Karen Van Nuys. (2024). Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at US Retail Pharmacies. JAMA. 332(15). 1298–1298.

Trish, Erin, Karen Van Nuys, Joanne Wu, & Nihar R. Desai. (2024). The Inflation Reduction Act and Patient Costs for Drugs to Treat Heart Failure. JAMA Network Open. 7(10). e2441915–e2441915. 1 indexed citations

Joyce, Geoffrey, Barbara Blaylock, Jiafan Chen, & Karen Van Nuys. (2024). Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011–20. Health Affairs. 43(3). 391–397. 5 indexed citations

Chen, Alice, et al.. (2023). Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share. Health Affairs. 42(6). 779–784. 2 indexed citations

Nuys, Karen Van, et al.. (2021). Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018. JAMA Health Forum. 2(11). e213409–e213409. 12 indexed citations

Trish, Erin, et al.. (2021). Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members. JAMA Internal Medicine. 181(10). 1414–1414. 12 indexed citations

10.

Cefalu, William T., Daniel Dawes, Dana P. Goldman, et al.. (2018). Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care. 41(6). 1299–1311. 174 indexed citations

11.

Nuys, Karen Van, et al.. (2018). Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs. JAMA. 319(10). 1045–1045. 13 indexed citations

12.

Nuys, Karen Van, et al.. (2017). The impact of broader hepatitis C treatment strategies on population health and social value in England. Journal of Hepatology. 66(1). S407–S407. 1 indexed citations

13.

Nuys, Karen Van, et al.. (2017). Economic study of the value of expanding HCV treatment capacity in Germany. BMJ Open Gastroenterology. 4(1). e000130–e000130. 7 indexed citations

14.

Dzau, Victor J., Geoffrey S. Ginsburg, Karen Van Nuys, David B. Agus, & Dana P. Goldman. (2015). Aligning incentives to fulfil the promise of personalised medicine. The Lancet. 385(9982). 2118–2119. 59 indexed citations

15.

Nuys, Karen Van, et al.. (2015). Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Affairs. 34(10). 1666–1674. 28 indexed citations

16.

Nuys, Karen Van, et al.. (2014). The Association between Employee Obesity and Employer Costs: Evidence from a Panel of U.S. Employers. American Journal of Health Promotion. 28(5). 277–285. 54 indexed citations

17.

Lanzetta, Paolo, et al.. (2011). The Economic Burden of Diabetic Macular Edema from a U.S. Private Payer Perspective. Investigative Ophthalmology & Visual Science. 52(14). 5532–5532. 6 indexed citations

18.

Ituarte, Philip H. G., et al.. (2011). Strategic Impact of a New Academic Endocrine Surgery Program. Annals of Surgical Oncology. 18(8). 2260–2264. 4 indexed citations

19.

Chen, Er, Marianne Laouri, Meghan Gallagher, et al.. (2010). Burden of illness of diabetic macular edema: literature review. Current Medical Research and Opinion. 26(7). 1587–1597. 115 indexed citations

20.

Nuys, Karen Van. (1993). Corporate governance through the proxy process. Journal of Financial Economics. 34(1). 101–132. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact